Ruyi Xia1, Hongmei Zeng2, Qian Liu3, Shuzheng Liu4, Zhiyi Zhang5, Yuqin Liu6, Guizhou Guo7, Guohui Song8, Yigong Zhu9, Xianghong Wu10, Bingbing Song11, Xianzhen Liao12, Yanfang Chen13, Wenqiang Wei2, Gang Chen14, Wanqing Chen2, Guihua Zhuang1. 1. Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China. 2. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. Xi'an Center for Disease Control and Prevention, Xi'an, China. 4. Henan Cancer Hospital, Zhengzhou, China. 5. Wuwei Cancer Hospital of Gansu Province, Wuwei, China. 6. Gansu Provincial Cancer Hospital, Lanzhou, China. 7. Linzhou Cancer Hospital, Linzhou, China. 8. Cixian Institute for Cancer Prevention and Control, Cixian Cancer Hospital, Handan, China. 9. Luoshan Center for Disease Control and Prevention, Xinyang, China. 10. Center for Disease Control and Prevention of Sheyang County, Yancheng, China. 11. Tumor Prevention and Treatment Institute, Harbin Medical University, Harbin, China. 12. Hunan Provincial Cancer Hospital, Changsha, China. 13. Yueyang Lou District Center for Disease Prevention and Control, Yueyang, China. 14. Centre for Health Economics, Monash Business School, Monash University, Melbourne, Vic., Australia.
Abstract
OBJECTIVE: To evaluate the health-related quality of life (HRQoL) and health state utility scores of gastric cancer patients in daily life at different clinical stages after treatment, and to explore influencing factors associated with HRQoL. METHODS: Gastric cancer patients discharged from hospitals and healthy controls identified by screening were recruited. The three-level EQ-5D was employed to assess HRQoL and was scored using two Chinese-specific tariffs published in 2014 and 2018. RESULTS: A total of 1,399 patients and 2,179 healthy controls were recruited. The likelihood of reporting problems in the five dimensions for patients was 4.0-23.8 times higher than controls. Based on the 2014/2018 tariff, the mean EQ-5D utility score was 0.321/0.163 lower than controls, and the mean utility scores of each patient subgroup were 0.077/0.039 (high-grade intraepithelial neoplasia/carcinoma in situ), 0.254/0.121 (Stage I), 0.249/0.123 (Stage II), 0.353/0.182 (Stage III) and 0.591/0.309 (Stage IV) lower than controls (all statistically significant). Age, occupation, duration of illness, other chronic disease status and therapeutic regimen had a significant impact upon different aspects of HRQoL in patients. CONCLUSIONS: Gastric cancer significantly impaired patients' HRQoL in daily life after treatment. More advanced cancer stages were associated with larger decrements on health state utility.
OBJECTIVE: To evaluate the health-related quality of life (HRQoL) and health state utility scores of gastric cancerpatients in daily life at different clinical stages after treatment, and to explore influencing factors associated with HRQoL. METHODS:Gastric cancerpatients discharged from hospitals and healthy controls identified by screening were recruited. The three-level EQ-5D was employed to assess HRQoL and was scored using two Chinese-specific tariffs published in 2014 and 2018. RESULTS: A total of 1,399 patients and 2,179 healthy controls were recruited. The likelihood of reporting problems in the five dimensions for patients was 4.0-23.8 times higher than controls. Based on the 2014/2018 tariff, the mean EQ-5D utility score was 0.321/0.163 lower than controls, and the mean utility scores of each patient subgroup were 0.077/0.039 (high-grade intraepithelial neoplasia/carcinoma in situ), 0.254/0.121 (Stage I), 0.249/0.123 (Stage II), 0.353/0.182 (Stage III) and 0.591/0.309 (Stage IV) lower than controls (all statistically significant). Age, occupation, duration of illness, other chronic disease status and therapeutic regimen had a significant impact upon different aspects of HRQoL in patients. CONCLUSIONS:Gastric cancer significantly impaired patients' HRQoL in daily life after treatment. More advanced cancer stages were associated with larger decrements on health state utility.
Authors: Ruo-Yu Zhang; Wei Wang; Hui-Jun Zhou; Jian-Wei Xuan; Nan Luo; Pei Wang Journal: Health Qual Life Outcomes Date: 2022-05-19 Impact factor: 3.077
Authors: Romy M van Amelsfoort; Karen van der Sluis; Winnie Schats; Edwin P M Jansen; Johanna W van Sandick; Marcel Verheij; Iris Walraven Journal: Cancers (Basel) Date: 2021-11-25 Impact factor: 6.639
Authors: Shuxia Qin; Xuehong Wang; Sini Li; Chongqing Tan; Xiaohui Zeng; Meiyu Wu; Ye Peng; Liting Wang; Xiaomin Wan Journal: Front Public Health Date: 2022-08-10